- Acne
- Actinic Keratosis
- Aesthetics
- Alopecia
- Atopic Dermatitis
- Buy-and-Bill
- COVID-19
- Case-Based Roundtable
- Chronic Hand Eczema
- Drug Watch
- Eczema
- General Dermatology
- Hidradenitis Suppurativa
- Melasma
- NP and PA
- Pediatric Dermatology
- Pigmentary Disorders
- Practice Management
- Precision Medicine and Biologics
- Prurigo Nodularis
- Psoriasis
- Psoriatic Arthritis
- Rare Disease
- Rosacea
- Skin Cancer
- Vitiligo
- Wound Care
News
Article
Daily Derm Times: March 27, 2025
Author(s):
Key Takeaways
- Nearly half of melanoma patients experience distress, affecting treatment adherence and quality of life.
- Tildrakizumab remains safe and effective for psoriasis after one year, improving patients' quality of life.
Catch up on dermatology news, highlights, and insights from the past 24 hours.
To stay up-to-date with the latest dermatology news, sign up to receive our eNewsletters.
Interview Intersection: Expert Interviews From March 2025
Dermatology Times is recapping our exclusive expert interviews from the month of March.
Understanding the Psychological Impact of Melanoma
Nearly half of patients with melanoma experience significant distress, affecting treatment adherence and quality of life.
Patient and Physician Perspectives Assess Long-Term Impact of Tildrakizumab for Psoriasis
Treatment with tildrakizumab was still safe and effective after 1 year with notable improvements in patients’ quality of life.
Novel Synthesized Silver Nanoparticle Shampoo is Comparable to 2% Ketoconazole for SD Treatment
In a prospective study, patients with scalp seborrheic dermatitis saw positive results in efficacy, safety, and quality of life when using the AgNP product.
Can BSZY Cream Reduce Symptoms of Facial Atopic Dermatitis?
The cream contains barrier-repairing ingredients that may enhance self-healing and hydration in affected skin.
Topical Xyngari Meets All Primary Endpoints in Phase 3 Study for Moderate to Severe Acne
Xyngari showed promise as the first once-weekly topical acne treatment, achieving strong phase 3 results with significant efficacy and safety.
